{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T17:40:32Z","timestamp":1791999632451,"version":"4.4.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T00:00:00Z","timestamp":1748476800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017655","name":"Incyte Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017655","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.jaad.2025.05.1385","type":"journal-article","created":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T19:31:45Z","timestamp":1747251105000},"page":"689-698","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Efficacy and safety of ruxolitinib cream in children aged 2 to 11 years with atopic dermatitis: Results from TRuE-AD3, a phase 3, randomized double-blind study"],"prefix":"10.1016","volume":"93","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2760-0474","authenticated-orcid":false,"given":"Lawrence F.","family":"Eichenfield","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda F.","family":"Stein Gold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric L.","family":"Simpson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea L.","family":"Zaenglein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"April W.","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megha M.","family":"Tollefson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weily","family":"Soong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Wine Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alim R.","family":"Devani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth B.","family":"Forman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dareen D.","family":"Siri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard","family":"Kallender","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett","family":"Angel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuejun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy S.","family":"Paller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2025.05.1385_bib1","doi-asserted-by":"crossref","DOI":"10.1089\/derm.2024.0165","article-title":"Prevalence of atopic dermatitis: a systematic review and meta-analysis","author":"Migliavaca","year":"2024","journal-title":"Dermatitis"},{"issue":"4","key":"10.1016\/j.jaad.2025.05.1385_bib2","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.anai.2020.12.020","article-title":"Atopic dermatitis in the pediatric population: a cross-sectional, international epidemiologic study","volume":"126","author":"Silverberg","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"3","key":"10.1016\/j.jaad.2025.05.1385_bib3","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/DER.0000000000000034","article-title":"Associations of childhood eczema severity: a US population-based study","volume":"25","author":"Silverberg","year":"2014","journal-title":"Dermatitis"},{"issue":"6","key":"10.1016\/j.jaad.2025.05.1385_bib4","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1093\/bjd\/ljad449","article-title":"Burden of atopic dermatitis in pediatric patients: an international cross-sectional study","volume":"190","author":"Weidinger","year":"2023","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2025.05.1385_bib5","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.jpeds.2022.04.027","article-title":"The family impact of atopic dermatitis in the pediatric population: results from an international cross-sectional study","volume":"246","author":"Barbarot","year":"2022","journal-title":"J Pediatr"},{"issue":"3","key":"10.1016\/j.jaad.2025.05.1385_bib6","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/bjd.16046","article-title":"Magnitude of benefit for topical crisaborole in the treatment of atopic dermatitis in children and adults does not look promising: a critical appraisal","volume":"178","author":"Ahmed","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2025.05.1385_bib7","doi-asserted-by":"crossref","DOI":"10.2340\/actadv.v103.6525","article-title":"Safety and efficacy of topical calcineurin inhibitors in the treatment of facial and genital psoriasis: a systematic review","volume":"103","author":"Amiri","year":"2023","journal-title":"Acta Derm Venereol"},{"issue":"3","key":"10.1016\/j.jaad.2025.05.1385_bib8","doi-asserted-by":"crossref","first-page":"144","DOI":"10.3109\/09546630903401470","article-title":"Two topical calcineurin inhibitors for the treatment of atopic dermatitis in pediatric patients: a meta-analysis of randomized clinical trials","volume":"21","author":"Chen","year":"2010","journal-title":"J Dermatolog Treat"},{"issue":"3","key":"10.1016\/j.jaad.2025.05.1385_bib9","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.jaad.2016.05.046","article-title":"Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults","volume":"75","author":"Paller","year":"2016","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"10.1016\/j.jaad.2025.05.1385_bib10","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1001\/jamadermatol.2024.3121","article-title":"Roflumilast cream, 0.15%, for atopic dermatitis in adults and children: INTEGUMENT-1 and INTEGUMENT-2 randomized clinical trials","volume":"160","author":"Simpson","year":"2024","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2025.05.1385_bib11","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.3389\/fimmu.2019.02342","article-title":"Targeting the Janus kinase family in autoimmune skin diseases","volume":"10","author":"Howell","year":"2019","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.jaad.2025.05.1385_bib12","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s40257-018-0413-2","article-title":"JAK inhibitors for atopic dermatitis: an update","volume":"20","author":"He","year":"2019","journal-title":"Am J Clin Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2025.05.1385_bib13","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1016\/j.jaci.2022.03.010","article-title":"Neuroimmune communication regulating pruritus in atopic dermatitis","volume":"149","author":"Steinhoff","year":"2022","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.jaad.2025.05.1385_bib14","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.cell.2017.08.006","article-title":"Sensory neurons co-opt classical immune signaling pathways to mediate chronic itch","volume":"171","author":"Oetjen","year":"2017","journal-title":"Cell"},{"issue":"15","key":"10.1016\/j.jaad.2025.05.1385_bib15","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1182\/blood-2009-04-214957","article-title":"Preclinical characterization of the selective JAK1\/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms","volume":"115","author":"Quint\u00e1s-Cardama","year":"2010","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.jaad.2025.05.1385_bib16","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.jaad.2021.04.085","article-title":"Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: results from 2 phase 3, randomized, double-blind studies","volume":"85","author":"Papp","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2025.05.1385_bib17","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.jaad.2022.09.060","article-title":"Long-term safety and disease control with ruxolitinib cream in atopic dermatitis: results from two phase 3 studies","volume":"88","author":"Papp","year":"2023","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2025.05.1385_bib18","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s40257-022-00690-3","article-title":"A maximum-use trial of ruxolitinib cream in adolescents and adults with atopic dermatitis","volume":"23","author":"Bissonnette","year":"2022","journal-title":"Am J Clin Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2025.05.1385_bib19","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s40257-024-00909-5","article-title":"A maximum-use trial of ruxolitinib cream in children aged 2-11 years with moderate to severe atopic dermatitis","volume":"26","author":"Stein Gold","year":"2025","journal-title":"Am J Clin Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2025.05.1385_bib20","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.anai.2022.12.033","article-title":"Safety, pharmacokinetics, and efficacy of ruxolitinib cream in children and adolescents with atopic dermatitis","volume":"130","author":"Leung","year":"2023","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"12","key":"10.1016\/j.jaad.2025.05.1385_bib21","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1001\/archderm.140.12.1513","article-title":"The patient-oriented eczema measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients' perspective","volume":"140","author":"Charman","year":"2004","journal-title":"Arch Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2025.05.1385_bib22","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1177\/0962280206074463","article-title":"Multiple imputation of discrete and continuous data by fully conditional specification","volume":"16","author":"van Buuren","year":"2007","journal-title":"Stat Methods Med Res"},{"issue":"4","key":"10.1016\/j.jaad.2025.05.1385_bib23","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1111\/bjd.17744","article-title":"Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate-to-severe atopic dermatitis","volume":"181","author":"Yosipovitch","year":"2019","journal-title":"Br J Dermatol"},{"issue":"12","key":"10.1016\/j.jaad.2025.05.1385_bib24","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1007\/s13555-022-00804-z","article-title":"Psychometric validation and responder definition of worst itch scale in children with severe atopic dermatitis","volume":"12","author":"Paller","year":"2022","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"8","key":"10.1016\/j.jaad.2025.05.1385_bib25","doi-asserted-by":"crossref","first-page":"3120","DOI":"10.1016\/j.jaip.2021.04.064","article-title":"Sleep disturbance in school-aged children with atopic dermatitis: prevalence and severity in a cross-sectional sample","volume":"9","author":"Fishbein","year":"2021","journal-title":"J Allergy Clin Immunol Pract"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962225021243?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962225021243?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T13:13:41Z","timestamp":1762262021000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962225021243"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S0190962225021243"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2025.05.1385","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of ruxolitinib cream in children aged 2 to 11 years with atopic dermatitis: Results from TRuE-AD3, a phase 3, randomized double-blind study","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2025.05.1385","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Incyte Corporation and The Authors. Published by Elsevier Inc. on behalf of the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}